Opportunistic gram-negative bacillary infections in leukemia. Oral manifestations during myelosuppression.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001419:Bacteria; D001424:Bacterial Infections / Q000209:etiology*; D002481:Cellulitis / Q000209:etiology; D004754:Enterobacter; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000209:etiology; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007710:Klebsiella Infections / Q000188:drug therapy / Q000209:etiology; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D009059:Mouth Diseases / Q000209:etiology*; D009061:Mouth Mucosa / Q000382:microbiology; D009912:Oral Manifestations; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology; D018805:Sepsis / Q000209:etiology; D012705:Serratia
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents